Περίληψη:
The use and interpretation of diagnostic cerebrospinal fluid (CSF) biomarkers for neu-rodegenerative disorders, such as Dementia with Lewy bodies (DLB), represent a clinical challenge. According to the literature, the composition of CSF in DLB patients varies. Some patients present with reduced levels of amyloid, others with full Alzheimer Disease CSF profile (both reduced amyloid and increased phospho-tau) and some with a normal profile. Some patients may present with abnormal levels of a-synuclein. Continuous efforts will be required to establish useful CSF biomarkers for the early diagnosis of DLB. Given the heterogeneity of methods and results between studies, further validation is fundamental before conclusions can be drawn. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Foska, A.
Tsantzali, I.
Sideri, E.
Stefanou, M.I.
Bakola, E.
Kitsos, D.K.
Zompola, C.
Bonakis, A.
Giannopoulos, S.
Voumvourakis, K.I.
Tsivgoulis, G.
Paraskevas, G.P.
